Arjo AB (ARRJF) AI Stock Analysis

Arjo AB

(Other OTC:ARRJF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Structural Care DemandUnderlying demand is supported by a growing number of patients requiring care, which can make Arjo’s products relevant across economic cycles. This structural need, combined with its focus on acute and long-term care, supports durable market opportunity and recurring replacement and service demand.

Negative Factors

Compressed ProfitabilityProfitability remains materially below prior years, limiting the earnings produced from Arjo’s revenue base and equity capital. Lower margins can reduce resilience to cost inflation or pricing pressure, while modest ROE suggests the company is not yet converting its capital base into returns as efficiently as before.

Arjo AB (ARRJF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $856.49M
Dividend Yield: 2.75%
Average Volume (3M): 9,400
Price to Earnings (P/E): 25.4
Beta (1Y): 0.45
Revenue Growth: 7.59%
EPS Growth: -9.51%
Country: US
Employees: 7,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

Arjo AB Business Overview & Revenue Model

Company Description

Arjo AB (publ) is a global leader in providing medical devices and innovative solutions tailored for patients experiencing limited mobility and age-related health conditions. Operating across North America, Western Europe, and other international mar...

Arjo AB Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|% Change Since:21.38%|Next Earnings Date:Jan 27, 2027

Earnings Call SentimentPositive

The call was predominantly positive, supported by 6% organic growth, stronger gross profit and adjusted EBIT, improved reported margins, higher operating cash flow, and lower leverage. Management also highlighted strong momentum in patient handling, North America, and Europe, along with a SEK 350 million EBIT improvement plan. Offsetting issues included higher restructuring costs, weaker quarterly performance in international and distributor-led markets, less favorable working capital, negative investment cash flow, revaluation losses, and uncertainty around the flu season's effect on the fourth quarter.

Positive Updates

Solid Organic Growth

Arjo delivered 6% organic growth in Q3, with positive development throughout all three months of the quarter and momentum carried over from the strong finish to Q2.

Negative Updates

International and Distributor-Led Markets Lagged in the Quarter

International and distributor-led markets did not deliver similarly strong growth during the quarter, although management said they were performing well year-to-date.

Company Guidance

Arjo reiterated a SEK 350 million commitment of profit improvements until H1 2029, described as a SEK 350 million profit improvement it believes it will be able to deliver by mid-2029, with the improvement being EBIT improvement; restructuring costs were “conservatively mentioned,” the company hopes it “will not need all of this,” and “the majority will happen largely over the coming 18 months.” Arjo will report progress every quarter, present new financial targets during Q1 2027, publish the year-end report at the end of January, and report Q1 in April 2027.

Arjo AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

ARRJF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:ALIF.B	74Outperform	SEK 22.23B	34.66	11.32%	0.82%	1.62%	63.45%
SE:XVIVO	64Neutral	SEK 6.46B	50.12	5.89%	―	17.83%	330.94%
SE:ASKER	58Neutral	SEK 27.32B	40.00	―	0.55%	―	―
SE:BACTI.B	53Neutral	SEK 560.70M	88.89	1.93%	―	-0.51%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:SEDANA	49Neutral	SEK 926.81M	-26.86	-3.88%	―	0.42%	15.03%

* Healthcare Sector Average

Performance Comparison

ARRJF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ARRJF	Arjo AB Class B	3.44	0.35	11.35%
SE:ALIF.B	AddLife AB Class B	182.30	-17.62	-8.81%
SE:XVIVO	Xvivo Perfusion AB	205.00	22.50	12.33%
SE:BACTI.B	Bactiguard Holding AB	16.00	-1.00	-5.88%
SE:SEDANA	Sedana Medical AB	9.33	-0.83	-8.17%
SE:ASKER	Asker Healthcare Group AB	71.20	-16.88	-19.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Arjo AB AI Stock Analysis